In their search for a possible treatment for Zika virus infection, a team of Indian researchers has identified a viral protein that can be targeted by an already available antimalarial drug, hydroxychloroquine (HCQ).
Researchers hit upon the protein when they conducted a high throughput virtual screening of a library of drugs approved by America’s Food and Drugs Authority. Of 1861 compounds in the library, five, including HCQ appeared to be possible candidates for treating the Zika virus. It has also been found that HCQ limits the Zika virus transmission from mother to fetus.
The study was conducted by researchers at the Indian Institute of Technology, Mandi, Alagappa University in Karaikudi, Tamil Nadu, and Washington University in St. Louis.
“Hopefully, we are close to finding a potential drug against Zika. We have successfully identified the target protein on which HCQ acts. Since it is an FDA-approved drug, our journey for validation may be less tedious, and we can go for preclinical trials faster,” said Dr. Rajanish Giri, a researcher at IIT Mandi, while speaking with India Science Wire.
“Repurposing approved drugs can be an efficient method to identify drug compounds, which may be capable of activating or inhibiting new targets. This approach has some advantageous features, including reduced development time and expense and improved safety” he added.
Zika gets transmitted by the bite of an infected mosquito from the Aedes genus, mainly Aedes aegypti. This is the same mosquito that transmits dengue, chikungunya, and yellow fever.
This virus infection during pregnancy is a cause of microcephaly (reduced head size) and other congenital abnormalities in developing fetuses and newborns. Zika infection in pregnancy also results in pregnancy like fetal loss, stillbirth, and preterm birth. Further, it is known to be associated with certain neurological disorders like Guillain-Barré syndrome in adults and cause problems like neuropathy and myelitis, particularly in older children and adults. The rapid spread of this virus in recent years has led to a surge in efforts to find an effective therapeutic intervention.
The researchers include Dr.Rajanish Giri from IIT Mandi, Prof. Indira U. Mysorekar from Washington University, and Prof. Sanjeev Kumar Singh from Alagappa University. A paper on the work has been recently published in the journal ACS Omega.
Journal Reference
- Ankur Kumar, Brooke Liang, Murali Aarthy, Sanjeev Kumar Singh, Neha Garg, Indira U. Mysorekar, and Rajanish Giri*. Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease. ACS Omega 2018, 3, 12, 18132-18141, December 24, 2018. DOI: 10.1021/acsomega.8b01002